Tricida, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 57
- Market Cap
- -
- Website
- http://www.tricida.com
Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis
Phase 3
Terminated
- Conditions
- Chronic Kidney DiseaseMetabolic Acidosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2022-10-14
- Lead Sponsor
- Tricida, Inc.
- Target Recruit Count
- 1480
- Registration Number
- NCT03710291
- Locations
- 🇸🇰
Investigative Site 2606, Košice, Slovakia
🇸🇰Investigative Site 2603, Svidník, Slovakia
🇺🇸Investigative Site 4122, Hollywood, Florida, United States
Long-term Safety Extension to Study TRCA-301
- First Posted Date
- 2018-01-04
- Last Posted Date
- 2021-10-22
- Lead Sponsor
- Tricida, Inc.
- Target Recruit Count
- 196
- Registration Number
- NCT03390842
- Locations
- 🇬🇪
Investigative Site 35, Tbilisi, Georgia
🇬🇪Investigative Site 36, Tbilisi, Georgia
🇬🇪Investigative Site 37, Tbilisi, Georgia
Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
- First Posted Date
- 2017-10-23
- Last Posted Date
- 2021-04-26
- Lead Sponsor
- Tricida, Inc.
- Target Recruit Count
- 217
- Registration Number
- NCT03317444
- Locations
- 🇬🇪
Investigative Site 32, Tbilisi, Georgia
🇬🇪Investigative Site 33, Tbilisi, Georgia
🇬🇪Investigative Site 36, Tbilisi, Georgia
Evaluation of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
- First Posted Date
- 2016-06-22
- Last Posted Date
- 2020-01-14
- Lead Sponsor
- Tricida, Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT02809183
- Locations
- 🇬🇪
Investigative Site 3, Tbilisi, Georgia
🇬🇪Investigative Site 6, Tbilisi, Georgia
🇧🇬Investigative Site 1, Sofia, Bulgaria
© Copyright 2025. All Rights Reserved by MedPath